I. OVERVIEW OF THE FUNDING OPPORTUNITY

Program Announcement for the Department of Defense

Defense Health Program

Congressionally Directed Medical Research Programs

Breast Cancer Research Program

Clinical Research Extension Award

Announcement Type: Modified

Funding Opportunity Number: HT9425-23-BCRP-CREA2

Assistance Listing Number: 12.420 Military Medical Research and Development

SUBMISSION AND REVIEW DATES AND TIMES

- Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), June 6, 2023
- Application Submission Deadline: 11:59 p.m. ET, June 22, 2023
- End of Application Verification Period: 5:00 p.m. ET, June 27, 2023
- Peer Review: August 2023
- Programmatic Review: November 2023
TABLE OF CONTENTS

I. OVERVIEW OF THE FUNDING OPPORTUNITY ................................................................. 1

II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY .................. 3

   II.A. Program Description ............................................................................................. 3
           II.A.1. The Breast Cancer Landscape ................................................................. 3
           II.A.2. FY23 BCRP Overarching Challenges ....................................................... 3

   II.B. Award Information ............................................................................................... 4

   II.C. Eligibility Information .......................................................................................... 7
           II.C.1. Eligible Applicants ....................................................................................... 7
           II.C.2. Cost Sharing ............................................................................................... 8
           II.C.3. Other ........................................................................................................... 9

   II.D. Application and Submission Information ............................................................ 9
           II.D.1. eBRAP and Grants.gov .............................................................................. 9
           II.D.2. Content and Form of the Application Submission ......................................... 10
           II.D.3. Unique Entity Identifier (UEI) and System for Award Management (SAM) ... 26
           II.D.4. Submission Dates and Times ........................................................................ 26
           II.D.5. Funding Restrictions .................................................................................... 27
           II.D.6. Other Submission Requirements ................................................................... 28

   II.E. Application Review Information .......................................................................... 28
           II.E.1. Criteria .......................................................................................................... 28
           II.E.2. Application Review and Selection Process ...................................................... 32
           II.E.3. Integrity and Performance Information ............................................................ 33
           II.E.4. Anticipated Announcement and Federal Award Dates ................................... 33

   II.F. Federal Award Administration Information ......................................................... 33
           II.F.1. Federal Award Notices .................................................................................. 33
           II.F.2. Administrative and National Policy Requirements ......................................... 34
           II.F.3. Reporting ....................................................................................................... 35

   II.G. Federal Awarding Agency Contacts .................................................................... 36
           II.G.1. eBRAP Help Desk ....................................................................................... 36
           II.G.2. Grants.gov Contact Center ......................................................................... 36

   II.H. Other Information ................................................................................................. 36
           II.H.1. Program Announcement and General Application Instructions Versions .......... 36
           II.H.2. Administrative Actions ............................................................................... 36
           II.H.3. Application Submission Checklist .................................................................. 39

APPENDIX 1: ACRONYM LIST ......................................................................................... 41
II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY

II.A. Program Description

Applications to the Fiscal Year 2023 (FY23) Breast Cancer Research Program (BCRP) are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The execution management agent for this program announcement is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC). The BCRP was initiated in FY92 to support innovative, high-impact research, with a mission of ending breast cancer for Service Members, Veterans, and the general public. Appropriations for the BCRP from FY92 through FY22 totaled $4.09 billion. The FY23 appropriation is $150 million (M).

The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer. Specifically, the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations.

II.A.1. The Breast Cancer Landscape

The BCRP has prepared a brief overview, The Breast Cancer Landscape, that describes what is currently known about the most pertinent topics that are consistent with the BCRP’s mission of ending breast cancer. Applicants are strongly urged to read and consider The Breast Cancer Landscape before preparing their applications. The Breast Cancer Landscape may be found at https://cdmrp.health.mil/bcrp/pdfs/BreastCancerLandscape2022.pdf.

II.A.2. FY23 BCRP Overarching Challenges

Considering the current breast cancer landscape and the BCRP’s mission, all FY23 BCRP Clinical Research Extension Award applications must address at least one of the following overarching challenges unless adequate justification for exception is provided.* Simply identifying an overarching challenge is not sufficient. Applications must address the challenge in a way that will have a major impact.

- Prevent breast cancer (primary prevention)
- Identify determinants of breast cancer initiation, risk, or susceptibility
- Distinguish deadly from non-deadly breast cancers
- Conquer the problems of overdiagnosis and overtreatment
- Identify what drives breast cancer growth; determine how to stop it
- Identify why some breast cancers become metastatic
• Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence

• Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival

• Eliminate the mortality associated with metastatic breast cancer

*Alternatively, with adequate justification, applications may identify and address another overarching challenge related to the breast cancer landscape. Justification must be provided in the application.

II.B. Award Information

The FY23 BCRP Clinical Research Extension Award aims to extend the data collection, follow-up, and analysis of breast cancer clinical research studies. The intent of this mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to limited or early termination of patient follow-up and sample collection and analysis. The critical components of this award mechanism are:

Impact: Research supported by the FY23 BCRP Clinical Research Extension Award will have the potential for a major impact and accelerate progress toward ending breast cancer. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research.

Research Scope: Although not all-inclusive, research proposed under the FY23 BCRP Clinical Research Extension Award may entail a deeper molecular analysis of clinical samples, initiation of new correlative studies, biomarker validation, or continuing clinical follow-up of patients currently/previously enrolled in an open/ongoing or completed clinical trial. The proposed research may be hypothesis testing/generating or may be designed to generate clinically annotated and molecularly characterized experimental platforms, including patient-derived models or tissue arrays. The award may not be used to directly support a clinical trial.

Feasibility: Preliminary data to support the scientific rationale and feasibility of the research approaches are required. The applicant must demonstrate availability of, and accessibility to, the necessary resources or populations to accomplish the proposed research.

Data Evaluation and Sharing: Proposed research should be based on study sample size that will ensure that the results support valid conclusions and further translation toward clinical application. It is the applicant’s responsibility to provide sufficient evidence that the sample size is appropriate to meet the study's objectives. The applicant must outline a plan to share the experimental platforms and molecular data generated from the proposed research with the scientific community.

Partnering PI Option: The FY23 BCRP Clinical Research Extension Award encourages applications that include meaningful and productive partnerships between investigators. The Partnering PI Option is structured to accommodate two Principal Investigators (PIs). One PI will
be identified as the Initiating PI and will be responsible for the majority of the administrative
tasks associated with application submission. The other PI will be identified as a Partnering PI.
The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected
to bring a distinct contribution to the application; partnerships between basic science and
clinical researchers are highly encouraged. Both PIs should contribute significantly to the
development of the proposed research project, including the Project Narrative, Statement of
Work (SOW), and other required components. The application should clearly demonstrate that
both PIs have equal intellectual input into the design of the project and will devote similar and
appropriate levels of effort to the conduct of the project. It is expected that funding will be
balanced between both PIs unless appropriately justified. The application is expected to describe
how the PIs’ unique expertise combined as a partnership will better address the research
question, how the unique expertise that each individual brings to the application is critical for the
research strategy and completion of the SOW, and why the work should be done together rather
than through separate efforts. Applicants are discouraged from being named as a PI, Initiating
PI, or Partnering PI on multiple Clinical Research Extension Award applications unless they
are clearly addressing distinct research questions. If recommended for funding, each PI will be
named to an individual award within the recipient organization. For individual submission
requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the
Application Submission.

Personnel: Applications are expected to include an appropriate and robust research team with
the combined backgrounds and breast cancer-related expertise to enable successful conduct of
the project.

Consumer Advocates: Applications are required to include consumer advocate involvement.
The research team must include two or more breast cancer consumer advocates, and it is the
applicant’s responsibility to outline the advocates’ role in the design and execution of the study.
As lay representatives, the consumer advocates must be individuals who have been diagnosed
with breast cancer and are actively involved in a breast cancer advocacy organization. Their role
should be independent of their employment, and they may not be employees of any organizations
participating in the application. The consumer advocates should have a high level of knowledge
of current breast cancer issues and the appropriate background and/or training in breast cancer
research to contribute to the project. Their role should be focused on providing objective input
throughout the research effort and its potential impact for individuals with, or at risk for, breast
cancer.

A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of
identifying ways to help accelerate clinical and translational research aimed at extending the
lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task
Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within
the limitations of this funding opportunity and fit within the FY23 BCRP priorities.

The proposed research must be relevant to active-duty Service Members, Veterans, military
beneficiaries, and/or the American public. Collaborations between researchers at military or
Veteran institutions and non-military institutions are strongly encouraged. These relationships
can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military families, and the American public.

The types of awards made under the program announcement will be assistance agreements. An assistance agreement is appropriate when the federal government transfers a “thing of value” to a “state, local government,” or “other recipient” to carry out a public purpose of support or stimulation authorized by a law of the United States instead of acquiring property or service for the direct benefit and use of the U.S. government. An assistance agreement can take the form of a grant or cooperative agreement. The level of involvement on the part of the Department of Defense (DOD) during project performance is the key factor in determining whether to award a grant or cooperative agreement. If “no substantial involvement” on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304). Conversely, if substantial involvement on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305), and the award will identify the specific substantial involvement. Substantial involvement may include, but is not limited to, collaboration, participation, or intervention in the research to be performed under the award. The award type, along with the start date, will be determined during the negotiation process.

The anticipated direct costs budgeted for the entire period of performance for an FY23 BCRP Clinical Research Extension Award should not exceed $5M for applications with a single PI or $6M if applying under the Partnering PI Option. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Awards will be made no later than September 30, 2024. For additional information refer to Section II.F.1, Federal Award Notices.

The CDMRP expects to allot approximately $17.1M to fund approximately two Clinical Research Extension Award applications. Funding of applications received is contingent upon the availability of federal funds for this program as well as the number of applications received, the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY23 funding opportunity will be funded with FY23 funds, which will expire for use on September 30, 2029.

Research Involving Human Data, Human Anatomical Substances, Human Subjects, or Human Cadavers: All DOD-funded research involving new and ongoing research with human data, human anatomical substances, human subjects, or human cadavers must be reviewed and approved by the USAMRDC Office of Human and Animal Research Oversight (OHARO), Office of Human Research Oversight (OHRO), prior to research implementation. This administrative review requirement is in addition to the local Institutional Review Board (IRB) or Ethics Committee (EC) review. Local IRB/EC approval at the time of application submission is not required; however, local IRB/EC approval is necessary prior to OHRO review. Allow up to 3 months to complete the OHRO regulatory review and approval process following submission of all required and complete documents to the OHRO. Refer to the General Application
As of January 20, 2020, U.S. institutions engaged in non-exempt cooperative research must rely on a single IRB to review and approve the portion of the research conducted at domestic sites in accordance with Code of Federal Regulations, Title 45, Part 46.114(b) (45 CFR 46.114[b]). If the proposed, non-exempt research involves more than one U.S.-based institution, a written plan for single IRB review arrangements must be provided at the time of application submission or award negotiation. The lead institution responsible for developing the master protocol and master consent form should be identified and should be the single point of contact for regulatory submissions and requirements.

Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed under this funding opportunity. A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.

Clinical research encompasses research with patient samples, data, and interaction with patients that may or may not be considered a clinical trial. For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research is observational in nature and includes: (1) Research that does not seek to evaluate the effects of interventions. Research conducted with human subjects (or on material of human origin such as data, tissues, specimens, and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects, but does not seek to assess the effects of an intervention, qualifies as clinical research. Patient-oriented research may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to study the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human tissues that cannot be linked to a living individual. Note: Studies that meet the requirements for exemption under §.104(d)(4) of the Common Rule are not considered clinical research as defined by CDMRP. Exemption category 4 refers to secondary research for which consent is not required.

II.C. Eligibility Information

II.C.1. Eligible Applicants

II.C.1.a. Organization: All organizations, including foreign organizations, foreign public entities, and international organizations, are eligible to apply.
Government Agencies Within the United States: Local, state, and federal government agencies are eligible to the extent that applications do not overlap with their fully funded internal programs. Such agencies are required to explain how their applications do not overlap with their internal programs.

As applications for this program announcement may be submitted by extramural and intramural organizations, these terms are defined below.

Extramural Organization: An eligible non-DOD organization. Examples of extramural organizations include academic institutions, biotechnology companies, foundations, federal government organizations other than the DOD, and research institutes.

Intramural DOD Organization: A DOD laboratory, DOD military treatment facility, and/or DOD activity embedded within a civilian medical center. Intramural Submission: An application submitted by a DOD organization for an intramural investigator working within a DOD laboratory or military treatment facility or in a DOD activity embedded within a civilian medical center.

The USAMRAA makes awards to eligible organizations, not to individuals.

II.C.1.b. Principal Investigator

Investigators at all academic levels (or equivalent) are eligible to be named as a PI, Initiating PI, or Partnering PI on an application.

There are no limitations on the number of applications for which an investigator may be named as a PI, Initiating PI, or Partnering PI.

Investigators are discouraged from being named as a PI, Initiating PI, or Partnering PI on multiple FY23 BCRP Clinical Research Extension Award applications unless they are clearly addressing distinct research questions. Applications will be required to include a brief description of all the applications in which the PI is named as a PI, Initiating PI, Partnering PI, or collaborator under this Clinical Research Extension Award program announcement.

An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by or affiliated with an eligible organization.

The CDMRP strongly encourages all PIs to participate in a digital identifier initiative through Open Researcher and Contributor ID, Inc. (ORCID). Registration for a unique ORCID identifier can be done online at https://orcid.org/.

II.C.2. Cost Sharing

Cost sharing/matching is not an eligibility requirement.
II.C.3. Other

Organizations must be able to access .gov and .mil websites in order to fulfill the financial and technical deliverable requirements of the award and submit invoices for payment.

For general information on required qualifications for award recipients, refer to the General Application Instructions, Appendix 3.

Refer to Section II.H.2, Administrative Actions, for a list of administrative actions that may be taken if a pre-application or application does not meet the administrative, eligibility, or ethical requirements defined in this program announcement.

II.D. Application and Submission Information

*Submission of applications that are essentially identical or propose essentially the same research project to different funding opportunities within the same program and funding cycle is prohibited and will result in administrative withdrawal of the duplicative application(s).*

II.D.1. eBRAP and Grants.gov

The electronic Biomedical Research Application Portal (eBRAP) ([https://ebrap.org](https://ebrap.org)) is a secure web-based system that allows PIs to submit their pre-applications, view and verify extramural full applications submitted to Grants.gov ([https://grants.gov](https://grants.gov)), receive communications from the CDMRP, and submit documentation during award negotiations and throughout the period of performance. eBRAP also allows intramural organizations to submit full applications following pre-application submission.

**Grants.gov** is a federal system required to be utilized by agencies to receive and process extramural grant applications. Full applications may only be submitted to Grants.gov after submission of a pre-application through eBRAP.

Contact information for the eBRAP Help Desk and the Grants.gov Contact Center can be found in Section II.G, Federal Awarding Agency Contacts.

**Extramural Submission:**

- Pre-application content and forms must be accessed and submitted at eBRAP.org.
- Full application packages must be accessed and submitted at Grants.gov.

**Intramural DOD Submission:**

- Pre-application content and forms must be accessed and submitted at eBRAP.org.
- Full application packages must be accessed and submitted at eBRAP.org.

*Note: Applications from an intramural DOD organization or from an extramural federal government organization may be submitted to Grants.gov through a research foundation.*
II.D.2. Content and Form of the Application Submission

Submission is a two-step process requiring both pre-application (eBRAP.org) and full application (eBRAP.org or Grants.gov) as indicated below. The submission process should be started early to avoid missing deadlines. There are no grace periods. Full application submission guidelines differ for extramural (Grants.gov) and intramural (eBRAP.org) organizations (refer to Table 1, Full Application Guidelines).

The application title, eBRAP log number, and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify, and verify the application in eBRAP. If any changes need to be made, the applicant should contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507 prior to the application submission deadline.

Partnering PI Option: The Initiating PI must complete the pre-application submission process and submit the contact information for the Partnering PI. The Partnering PI will then be notified of the pre-application submission separately by email. The Partnering PI must follow the link in the notification email to associate the partnering pre-application with their eBRAP account. After associating the pre-application to their eBRAP account, the Partnering PI should email the eBRAP Helpdesk (help@ebrap.org) to have the desired contact information associated to their pre-application. The email should include the pre-application log number, the name of the Business Official, the name(s) of the Performing/Contracting Organization(s), and the submission-type for the pre-application (extramural or intramural). If not previously registered, the Partnering PI must register in eBRAP. A new pre-application based on this research project should not be initiated by the Partnering PI. Applicants are urged to complete these steps as soon as possible. If they are not completed, the Partnering PI will not be able to view and modify their application during the verification period in eBRAP. If these steps are not completed, an intramural partner will not be able to submit the Partnering PI’s required full application package components to eBRAP.

II.D.2.a. Step 1: Pre-Application Submission Content

During the pre-application process, eBRAP assigns each submission a unique log number. This unique eBRAP log number is required during the full application submission process.

To begin the pre-application process, first select whether the submitting organization is extramural or intramural, then confirm your selection or cancel. Incorrect selection of extramural or intramural submission type will delay processing.

If an error has been made in the selection of extramural versus intramural and the pre-application submission deadline has passed, the PI or Business Official must contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507 to request a change in designation.

All pre-application components must be submitted by the PI (single PI) or Initiating PI (Partnering PI Option) through eBRAP (https://eBRAP.org/).
The applicant organization and associated PI(s) identified in the pre-application should be the same as those intended for the subsequent application submission. If any changes are necessary after submission of the pre-application, the applicant must contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507.

PIs with an ORCID identifier should enter that information in the appropriate field in the “My Profile” tab in the “Account Information” section of eBRAP.

When starting the pre-application, PIs should ensure that they have selected the appropriate mechanism option in eBRAP:

- CREA – Clinical Research Extension Award
- CREA-PPIO – Clinical Research Extension Award – Partnering PI Option

The pre-application consists of the following components, which are organized in eBRAP by separate tabs (refer to the General Application Instructions, Section II.B, for additional information on pre-application submission):

- **Tab 1 – Application Information**

  Submission of application information includes assignment of primary and secondary research classification codes, which may be found at https://ebrap.org/eBRAP/public/Program.htm. Applicants are strongly encouraged to review and confirm the codes prior to making their selection.

- **Tab 2 – Application Contacts**

  Enter contact information for the PI. Enter the organization’s Business Official responsible for sponsored program administration (the “person to be contacted on matters involving this application” in Block 5 of the Grants.gov SF424 Research & Related Form). The Business Official must be either selected from the eBRAP list or invited in order for the pre-application to be submitted.

  Select the performing organization (site at which the PI will perform the proposed work) and the contracting organization (organization submitting on behalf of the PI, which corresponds to Block 5 on the Grants.gov SF424 Research & Related Form), and click on “Add Organizations to this Pre-application.” The organization(s) must be either selected from the eBRAP drop-down list or invited in order for the pre-application to be submitted.

  It is recommended that applicants identify an Alternate Submitter in the event that assistance with pre-application submission is needed.

- **Tab 3 – Collaborators and Key Personnel**

  Enter the name, organization, and role of all collaborators and key personnel associated with the application.
**FY23 BCRP Programmatic Panel members** should not be involved in any pre-application or application. For questions related to panel members and pre-applications or applications, refer to **Section II.H.2.c, Withdrawal**, or contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507.

**Partnering PI Option:** The Initiating PI must enter the contact information for the Partnering PI in the Partnering PI section.

- **Tab 4 – Conflicts of Interest**

  List all individuals other than collaborators and key personnel who may have a conflict of interest in the review of the application (including those with whom the PI has a personal or professional relationship).

- **Tab 5 – Pre-Application Files**

  **Letter of Intent (LOI) (one-page limit):** Provide a brief description of the research to be conducted. LOIs are used for program planning purposes only (e.g., reviewer recruitment) and will not be reviewed during either the peer or programmatic review sessions. An invitation to submit is **not** required.

- **Tab 6 – Submit Pre-Application**

  This tab must be completed for the pre-application to be accepted and processed.

**II.D.2.b. Step 2: Full Application Submission Content**

*The CDMRP cannot make allowances/exceptions to its policies for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.*

Each application submission must include the completed full application package for this program announcement. The full application package is submitted by the Authorized Organizational Representative through Grants.gov (https://grants.gov/) for extramural organizations or through eBRAP (https://ebrap.org/) for intramural organizations. See Table 1 below for more specific guidelines.

**II.D.2.b.i. Full Application Guidelines**

Extramural organizations must submit full applications through Grants.gov. Applicants must create a Grants.gov Workspace for submission, which allows the application components to be completed online and routed through the applicant organization for review prior to submission. Applicants may choose to download and save individual PDF forms rather than filling out webforms in Workspace. A compatible version of Adobe Reader must be used to view, complete, and submit an application package consisting of PDF forms. If more than one person is entering text into an application package, the same version of Adobe Reader software should be used by each person. Check the version number of the Adobe software on each user’s computer to make sure the versions match. Using different versions of Adobe Reader may cause submission and/or save errors – even if each version is individually compatible with Grants.gov.

*Do not password protect any files of the application package, including the Project Narrative.*

Table 1. Full Application Submission Guidelines

<table>
<thead>
<tr>
<th>Extramural Submissions</th>
<th>Intramural DOD Submissions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Application Package Location</strong></td>
<td>Download application package components for HT9425-23-BCRP-CREA2 from Grants.gov (<a href="https://grants.gov">https://grants.gov</a>) and create a Grants.gov Workspace. Workspace allows online completion of the application components and routing of the application package through the applicant organization for review prior to submission.</td>
</tr>
<tr>
<td><strong>Full Application Package Components</strong></td>
<td><strong>Tab 1 – Summary:</strong> Provide a summary of the application information.</td>
</tr>
<tr>
<td>SF424 Research &amp; Related Application for Federal Assistance Form:</td>
<td><strong>Tab 2 – Application Contacts:</strong> This tab will be pre-populated by eBRAP; add Authorized Organizational Representative.</td>
</tr>
<tr>
<td>Refer to the General Application Instructions, Section III.A.1, for detailed information.</td>
<td><strong>Tab 3 – Full Application Files:</strong> Upload files under each Application Component in eBRAP. Descriptions of each required file can be found under Full Application Submission Components:</td>
</tr>
<tr>
<td>Descriptions of each required file can be found under Full Application Submission Components:</td>
<td>• Attachments&lt;br&gt;• Research &amp; Related Personal Data&lt;br&gt;• Research &amp; Related Senior/Key Person Profile (Expanded)&lt;br&gt;• Research &amp; Related Budget&lt;br&gt;• Project/Performance Site Location(s) Form&lt;br&gt;• Research &amp; Related Subaward Budget Attachment(s) Form</td>
</tr>
<tr>
<td><strong>Application Package Submission</strong></td>
<td><strong>Tab 4 – Application and Budget Data:</strong> Review and edit proposed project start date, proposed end date, and budget data pre-populated from the Budget Form.</td>
</tr>
<tr>
<td>Create a Grants.gov Workspace. Add participants (investigators and Business Officials) to Workspace, complete all required forms, and check for errors before submission.</td>
<td><strong>Submit package components to eBRAP (<a href="https://ebrap.org">https://ebrap.org</a>).</strong></td>
</tr>
<tr>
<td>Submit a Grants.gov Workspace Package.</td>
<td><strong>Tab 5 – Submit/Request Approval Full Application:</strong> After all components are uploaded and prior to the full application submission</td>
</tr>
<tr>
<td>Extramural Submissions</td>
<td>Intramural DOD Submissions</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>An application may be submitted through Workspace by clicking the “Sign and Submit” button on the “Manage Workspace” page, under the “Forms” tab. Grants.gov recommends submission of the application package <strong>at least 24-48 hours prior to the close date</strong> to allow time to correct any potential technical issues that may disrupt the application submission.</td>
<td>deadline, enter your password in the space provided next to “Enter Your Password Here” and press the “Submit Full Application” button. eBRAP will notify your Resource Manager/Comptroller/Task Area Manager or equivalent Business Official by email. <strong>Do not password protect any files of the application package, including the Project Narrative.</strong></td>
</tr>
<tr>
<td><strong>Note:</strong> If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated Grants.gov application package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID prior to the application submission deadline. <strong>Do not password protect any files of the application package, including the Project Narrative.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Application Verification Period</strong></td>
<td>After eBRAP has processed the full application, the organizational Resource Manager/Comptroller/Task Area Manager or equivalent Business Official and PI(s) will receive email notification of this status and will be able to view and modify application components in eBRAP. During the application verification period, the full application package may be modified <strong>with the exception of the Project Narrative and Research &amp; Related Budget Form.</strong> Your Resource Manager/Comptroller/Task Area Manager or equivalent Business Official should log into eBRAP to review and to approve prior to the application verification deadline.</td>
</tr>
<tr>
<td><strong>Further Information</strong></td>
<td>Refer to the General Application Instructions, Section IV, for further information regarding eBRAP requirements.</td>
</tr>
</tbody>
</table>

**Tracking a Grants.gov Workspace Package.** After successfully submitting a Workspace package, a Grants.gov Tracking Number is automatically assigned to the package. The number will be listed on the “Confirmation” page that is generated after submission. Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements.
**Partnering PI Option:** The CDMRP requires separate full application package submissions for the Initiating PI and each Partnering PI, even if the PIs are located within the same organization. Initiating and Partnering PIs will each be assigned a unique eBRAP log number. Each full application package must be submitted using the unique eBRAP log number. *Note: All associated applications (the Initiating PI’s and the Partnering PI’s) must be submitted by the full application submission deadline.*

The full application package must be submitted using the unique eBRAP log number to avoid delays in application processing.

**II.D.2.b.ii. Full Application Submission Components**

- **Extramural Applications Only**

  **SF424 Research & Related Application for Federal Assistance Form:** Refer to the General Application Instructions, Section III.A.1, for detailed information.

- **Extramural and Intramural Applications**

  **Attachments:**

  *Each attachment to the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Application Instructions, Appendix 4.*

  For all attachments, ensure that the file names are consistent with the guidance. Attachments will be rejected if the file names are longer than 50 characters or have incorrect file names that contain characters other than the following: A-Z, a-z, 0-9, underscore, hyphen, space, and period. In addition, there are file size limits that may apply in some circumstances. Individual attachments may not exceed 20 megabytes (MB), and the file size for the entire full application package may not exceed 200 MB.

  - **Attachment 1: Project Narrative (18-page limit): Upload as “ProjectNarrative.pdf”**. The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs (uniform resource locators) that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.

    Describe the proposed project in detail using the outline below.

    - **Background:** Present the ideas and reasoning behind the proposed research and the FY23 BCRP Overarching Challenge that will be addressed. The application must provide a sound scientific rationale to support the proposed project and its feasibility as established through the demonstration of logical reasoning and a critical review and analysis of published literature; include relevant literature citations. Describe
how the proposed work aims to extend the data collection, follow-up, and/or analysis of a breast cancer clinical research study (or studies). Include preliminary data to support the scientific rationale and feasibility of the research approaches. Describe the clinical relevance of the proposed research.

- **Hypothesis or Objective:** State the hypothesis to be tested or the objective to be reached.

- **Specific Aims:** Concisely explain the project’s specific aims to be funded by this application.

- **Research Strategy and Feasibility:**
  
  - Describe the experimental design, methods, and analyses, including appropriate sample-size estimation and controls, in sufficient detail for evaluation. Include information describing the availability of required resources, if applicable.
  
  - Address potential problem areas and present alternative methods and approaches.
  
  - Clearly describe the statistical model and data analysis plan including how it supports the stated hypothesis or objective. Include sample size projections and an appropriate power analysis, if applicable, to demonstrate that the sample size is appropriate to meet the objectives of the study.
  
  - If human subjects or human biological samples will be used, include a detailed plan for the recruitment of subjects or the acquisition of samples. Provide information to support the availability of and access to the appropriate resources, patient population(s), and/or samples. For clinical research, see Attachment 10 for the required strategy for the inclusion of women and minorities appropriate to the objectives of the study. *This award does not support clinical trials.*
  
  - For applications including correlative studies:
    
    - Describe the pre-existing cohort, including the type of data and/or biospecimens available.
    
    - Describe the size of the pre-existing cohort, including subjects and controls, and the expected statistical power of the study.
    
    - Explain how the cohort is appropriate for the study objective.
    
    - If applicable, describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the U.S. Food and Drug Administration (FDA).

- **Attachment 2: Supporting Documentation:** Combine and upload as a single file named “Support.pdf”. Start each document on a new page. If documents are scanned to PDF, the lowest resolution (100 to 150 dpi) should be used. The Supporting
Documentation attachment should not include additional information such as figures, tables, graphs, photographs, diagrams, chemical structures, or drawings. These items should be included in the Project Narrative.

There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

- **References Cited:** List the references cited (including URLs, if available) in the Project Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).

- **List of Abbreviations, Acronyms, and Symbols:** Provide a list of abbreviations, acronyms, and symbols.

- **Facilities, Existing Equipment, and Other Resources:** Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present government award under which the facilities or equipment items are now accountable. There is no form for this information.

- **Publications and/or Patents:** Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

- **Letters of Organizational Support:** Provide a letter (or letters, if applicable) signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project. Letters of support not requested in the program announcement, such as those from members of Congress, do not impact application review or funding decisions.

- **Letters of Collaboration (if applicable):** Provide a signed letter from each collaborating individual or organization demonstrating that the PI has the support or resources necessary for the proposed work. If an investigator at an intramural organization is named as a collaborator on an application submitted through an extramural organization, the application must include a letter from the collaborator’s Commander or Commanding Officer at the intramural organization that authorizes the collaborator’s involvement.

- **Consumer Advocate Letters of Commitment:** Provide a letter signed by each consumer advocate confirming their commitment to participate in the proposed project.
- **Letters of Support (if applicable):** Provide a signed letter from any organizations providing resources, data, and/or biospecimens for the proposed study that will demonstrate that the PI has the support and access to resources necessary for the proposed work.

- **Intellectual Property:** Information can be found in the 2 CFR 200.315, “Intangible Property.”
  
  - **Intellectual and Material Property Plan (if applicable):** Provide a plan for resolving intellectual and material property issues among participating organizations.

- **Data and Research Resources Sharing Plan:** Describe how data and resources generated during the performance of the project will be shared with the research community. Refer to the General Application Instructions, Appendix 2, Section K, for more information about the CDMRP expectations for making data and research resources publicly available.

- **Data Management Plan** (2-page limit): Describe the data management plan in accordance with Section 3.c. Enclosure 3, [DoD Instructions 3200.12](#).
  
  - For Extramural Applications: Refer to General Application Instructions, Section III.A.2, Attachments Form, Attachment 2, Supporting Documentation, for more detailed information.
  
  - For Intramural Applications: Refer to General Application Instructions, Section IV.A.1, Application Component – Attachments, Attachment 2, Supporting Documentation, for more detailed information.

- **Attachment 3: Technical Abstract (one-page limit):** Upload as “TechAbs.pdf”. The technical abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. *Do not include proprietary or confidential information.* Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

  Technical abstracts should be written using the outline below.

  - **Background:** Present the ideas and reasoning behind the proposed work.
  
  - **Overarching Challenge(s):** State the overarching challenge(s) that will be addressed.
  
  - **Hypothesis/Objective:** State the hypothesis to be tested or the objective to be reached. Provide evidence or rationale that supports the objective/hypothesis.
  
  - **Specific Aims:** State the specific aims of the study.
  
  - **Study Design:** Briefly describe the study design, including appropriate controls.
- **Impact**: Briefly describe how the project will increase the clinically relevant impact of breast cancer patient participation in clinical research. Describe how the proposed project will have a major impact for the overarching challenge(s) and accelerate progress toward ending breast cancer.

  - **Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf”.** The lay abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. **Do not include proprietary or confidential information.** Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

  - Clearly describe the rationale, objective, and aims of the application in a manner readily understood by readers without a background in science or medicine.
    - Do not duplicate the technical abstract.
  - Describe the ultimate applicability of the research.
    - Which overarching challenge(s) does the research address?
    - What types of patients or at-risk individuals will it help and how will it help them?
    - What are the potential clinical applications, benefits, and risks?
    - What is the projected time it may take to achieve a patient-related outcome?
    - How will the project increase the impact of breast cancer patient participation in clinical research?
    - What is the likely impact of this study on the BCRP’s mission of ending breast cancer?

  - **Attachment 5: Statement of Work (three-page limit): Upload as “SOW.pdf”.** The suggested SOW format and examples specific to different types of research projects are available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm). Recommended strategies for assembling the SOW can be found at https://ebrap.org/eBRAP/public/Program.htm.

    For the Clinical Research Extension Award, refer to either the “**Suggested SOW Strategy for Clinical Research**” or “**Suggested SOW Strategy Generic Research**”, whichever format is most appropriate for the proposed effort, and use the blank SOW format titled “Suggested SOW Format”. The SOW must be in PDF format prior to attaching.

    The SOW should indicate a feasible plan and timeline to conduct the research. The SOW must include specific research milestones to be accomplished by the end of each year in the period of performance.
Partnering PI Option: Each PI must submit an identical copy of a jointly created SOW. The contributions of the Initiating PI and the Partnering PI should be noted for each task.

○ Attachment 6: Impact Statement (300 words or less recommended; one-page limit): Upload as “Impact.pdf”. The impact statement should be written with a broad audience in mind, including readers without a background in science or medicine.

**DO NOT restate the research strategy as part of the Impact Statement.**

- Articulate concisely how the proposed extension of a clinical research study (or studies) will have a major impact on at least one of the overarching challenge(s).

- Explain how the proposed research will accelerate progress toward ending breast cancer.

- Describe how the project will increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to limited or early termination of follow-up and sample collection and analysis.

- Identify the breast cancer patients or at-risk individuals and justify how they would ultimately benefit from the proposed research.

○ Attachment 7: Partnership Statement (one-page limit): Upload as “Partnership.pdf”. (Attachment 7 is only applicable and required for applications submitted under the Partnering PI Option.) Describe the partnership and combined expertise of the Initiating and Partnering PIs that are critical for the research strategy and completion of the SOW. Explain how the partnership will better address the research question and why the work should be done together rather than through separate individual efforts. Explain how both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. Explain how funding will be balanced between both PIs or otherwise provide appropriate justification.

○ Attachment 8: Research Team Statement (one-page limit): Upload as “Team.pdf”. Describe how the PI’s and research team’s combined backgrounds and breast cancer-related expertise will contribute to accomplishing the research goals. Provide the names of at least two consumer advocates and their affiliation with a breast cancer advocacy organization(s). Describe how the consumer advocates’ knowledge of current breast cancer issues and how their background and/or training in breast cancer research will contribute to the proposed research. Explain how the consumer advocates will be integrated into the design and execution of the study.

○ Attachment 9: Transition Plan (two-page limit): Upload as “Transition.pdf”. Provide information on potential methods and strategies to feasibly move the project’s findings to the next phase of development, clinical trials, clinical implementation, and/or delivery to the commercial market after successful completion of the award. The transition plan should include the components listed below.
An assessment of the opportunities available (e.g., collaborations and other resources) and potential barriers that would impact the progress of commercializing and/or translating the study results into clinical practice.

A timeline with defined milestones and deliverables describing the expected post-award progress of the results toward clinical impact.

A detailed plan for distribution of the findings to the breast cancer community.

A detailed plan to share the experimental platforms and molecular data generated from the proposed research with the scientific community, if applicable.

- **Attachment 10**: Inclusion of Women and Minorities (four-page limit): Upload as “Inclusion.pdf”. *(Attachment 10 is only applicable and required for applications that propose clinical research.)* Describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex/gender, race, and ethnic group and an accompanying rationale for the selection of subjects. Provide an anticipated enrollment table(s) for the inclusion of women and minorities appropriate to the objectives of the study with the proposed enrollment distributed on the basis of sex/gender, race, and ethnicity. The Public Health Service (PHS) Inclusion Enrollment Report (a three-page fillable PDF form) can be downloaded from eBRAP under “Resources and Reference Material” at https://ebrap.org/eBRAP/public/Program.htm.

- **Attachment 11**: Submissions Statement (one-page limit): Upload as “Submissions.pdf”. *(Attachment 8 is only applicable and required for individuals who are named on multiple Clinical Research Extension Award applications. Attachment 11 will be available for programmatic review only.)* Provide the following information for each individual named as a PI, Initiating PI, Partnering PI, or collaborator in multiple FY23 BCRP Clinical Research Extension Award applications:
  - CDMRP log number, funding level, role on the project, project title, and specific aims
  - Brief description of how the application addresses a research question that is distinct from the other application(s)

- **Attachment 12**: Representations, if applicable (extramural submissions only): Upload as “RequiredReps.pdf”. All extramural applicants must complete and submit the Required Representations template available on eBRAP (https://ebrap.org/eBRAP/public/Program.htm). For more information, see the General Application Instructions, Appendix 5, Section B, Representations.

- **Attachment 13**: Suggested Collaborating DOD Military Facility Budget Format, if applicable: Upload as “MFBudget.pdf”. If a military facility (Military Health System facility, research laboratory, medical treatment facility, dental treatment facility, or a DOD activity embedded with a civilian medical center) will be a collaborator in performance of the project, complete a separate budget, using “Suggested Collaborating DOD Military Facility Budget Format”, available for download on the eBRAP “Funding
Opportunities & Forms” web page [https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm), including a budget justification, for each military facility as instructed. The costs per year should be included on the Grants.gov Research & Related Budget Form under subaward costs. Refer to the General Application Instructions, Section III.A.8, for detailed information.

- **Extramural and Intramural Applications**

To evaluate compliance with Title IX of the Education Amendments of 1972 (20 USC 1681[a] et seq.), the DOD is collecting certain demographic and career information to be able to assess the success rates of women who are proposed for key roles in applications in science, technology, engineering, and/or mathematics (STEM) disciplines. To enable this assessment, each application must include the following forms completed as indicated.

**Research & Related Personal Data:** For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.3, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.2, for detailed information.

**Research & Related Senior/Key Person Profile (Expanded):** For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.4, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.3, for detailed information.

  - **PI Biographical Sketch (five-page limit):** Upload as “Biosketch_LastName.pdf”. The suggested biographical sketch format is available on the “Funding Opportunities & Forms” web page ([https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm)) in eBRAP. The National Institutes of Health (NIH) Biographical Sketch may also be used. All biographical sketches should be submitted in uneditable PDF format.

  - **PI Previous/Current/Pending Support (no page limit):** Upload as “Support_LastName.pdf”.
    - For extramural submissions, refer to the General Application Instructions, Section III.A.4, for detailed information.
    - For intramural submissions, refer to the General Application Instructions, Section IV.A.3, for detailed information.

  - **Key Personnel Biographical Sketches (five-page limit each):** Upload as “Biosketch_LastName.pdf”.
    - Include biographical sketch for team members, including consumer advocates.
○ Key Personnel Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf”.
  
  – For extramural submissions, refer to the General Application Instructions, Section III.A.4, for detailed information.
  
  – For intramural submissions, refer to the General Application Instructions, Section IV.A.3, for detailed information.

Research & Related Budget: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.5, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.4, for detailed information.

Budget Justification (no page limit): Upload as “BudgetJustification.pdf”. The budget justification for the entire period of performance must be uploaded to the Research & Related Budget after completion of the budget for Period 1.

Partnering PI Option: Initiating and Partnering PIs must have a separate budget and justification specific to their distinct portions of the effort that the applicant organization will submit as separate Grants.gov or eBRAP application packages. The Initiating PI should not include budget information for Partnering PI(s) even if they are located within the same organization. Refer to Section II.D.5, Funding Restrictions, for detailed information.

Project/Performance Site Location(s) Form: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.6, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.5, for detailed information.

• Extramural Applications Only

Research & Related Subaward Budget Attachment(s) Form (if applicable): Refer to the General Application Instructions, Section III.A.7, for detailed information.

○ Extramural Subaward: Complete the Research & Related Subaward Budget Form through Grants.gov. (Refer to the General Application Instructions, Section III.A.7, for detailed information.) Verify subaward budget(s) and budget justification forms are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period.

○ Intramural DOD Collaborator(s): Complete the “Suggested Collaborating DOD Military Facility Budget Format” and upload to Grants.gov attachment form as Attachment 13. (Refer to the General Application Instructions, Section IV.A.4, for detailed information.) Each Intramural DOD Collaborator should include costs per year on the Grants.gov Research & Related Budget Form under subaward costs.
**Suggested DOD Military Budget Format:** A military facility collaborating in the performance of the project (but not participating as a Partnering PI) should be treated as a subaward for budget purposes. **Note:** Applicants should complete a separate military budget using “Suggested Collaborating DOD Military Facility Budget Format” (available for download on the eBRAP “Funding Opportunities & Forms” web page [https://ebrap.org/eBRAP/public/Program.htm]) (Attachment 13) to show all direct and indirect costs. The costs per year should be included on the Grants.gov Research & Related Budget Form under subaward costs. Refer to the General Application Instructions, Section III.A.8, for detailed information.

**Application Components for the Partnering PI, if applying under the Partnering PI Option**

The Partnering PI must follow the link in the email from eBRAP and, if not registered in eBRAP, must complete the registration process prior to the application submission deadline in order to associate their full application package with that of the Initiating PI.

For the Partnering PI, the Initiating PI must identify if the Partnering PI will be named on an extramural or intramural application (in accordance with the guidelines in Section II.C.1.a, Organization) and the appropriate mode of submission (Grants.gov for extramural and eBRAP for intramural). The Partnering PI must verify their contact information and mode of submission within eBRAP to ensure proper submission of their application.

The application submission process for the Partnering PI uses an abbreviated full application package that includes:

- **Extramural and Intramural Applications**

  **Attachments:**

  - **Attachment 5:** Statement of Work (three-page limit): Upload as “SOW.pdf”. Refer to the General Application Instructions, Section III.A.2, for detailed information on completing the SOW. Each PI must submit an identical copy of a jointly created SOW. The contributions of the Initiating PI and the Partnering PI should be noted for each task.

  - **Attachment 12:** Representations (extramural submissions only): Upload as “RequiredReps.pdf”. All extramural applicants must complete and submit the Required Representations template available on eBRAP [https://ebrap.org/eBRAP/public/Program.htm]. For more information, see the General Application Instructions, Appendix 5, Section B, Representations.

  - **Attachment 13:** Suggested Collaborating DOD Military Facility Budget Format: Upload as “MFBudget.pdf”. Refer to the General Application Instructions, Section IV.A.4, for detailed information. The costs per year should be included on the Grants.gov Research & Related Budget Form under subaward costs.

**Research & Related Personal Data:** For extramural submissions (via Grants.gov) refer to the General Application Instructions, Section III.A.3, and for intramural submissions (via
eBRAP), refer to the General Application Instructions, Section IV.A.2, for detailed information.

**Research & Related Senior/Key Person Profile (Expanded):** For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.4, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.3, for detailed information.

- **PI Biographical Sketch (five-page limit):** Upload as “Biosketch_LastName.pdf”. The suggested biographical sketch format is available on the “Funding Opportunities & Forms” web page ([https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm)) in eBRAP. The NIH Biographical Sketch may also be used. All biographical sketches should be submitted in the PDF format that is not editable.

- **PI Previous/Current/Pending Support (no page limit):** Upload as “Support_LastName.pdf”.
  - For extramural submissions, refer to the General Application Instructions, Section III.A.4, for detailed information.
  - For intramural submissions, refer to the General Application Instructions, Section IV.A.3, for detailed information.

- **Key Personnel Biographical Sketches (five-page limit each):** Upload as “Biosketch_LastName.pdf”.
  - Include biographical sketch for team members, including consumer advocates.

- **Key Personnel Previous/Current/Pending Support (no page limit):** Upload as “Support_LastName.pdf”.
  - For extramural submissions, refer to the General Application Instructions, Section III.A.4, for detailed information.
  - For intramural submissions, refer to the General Application Instructions, Section IV.A.3, for detailed information.

**Research & Related Budget:** For extramural submissions, refer to the General Application Instructions, Section III.A.5, and for intramural submissions, refer to the General Application Instructions, Section IV.A.4, for detailed information.

**Budget Justification (no page limit):** Upload as “BudgetJustification.pdf”.

*Initiating and Partnering PIs must each submit a budget and justification specific to their own portion of the efforts as part of their separate Grants.gov or eBRAP application packages. The Research & Related Budget for the Partnering PI should not include budget information for the Initiating PI, even if they are located within the same organization. Refer to Section II.D.5, Funding Restrictions, for detailed information.*
**Project/Performance Site Location(s) Form:** For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.6, and for intramural submissions (via eBRAP), refer to General Application Instructions, Section IV.A.5, for detailed information.

- **Extramural Applications Only**

  **Research & Related Subaward Budget Attachment(s) Form:**
  
  ○ **Extramural Subaward:** Complete the Research & Related Subaward Budget Form through Grants.gov. (Refer to the General Application Instructions, Section III.A.7, for detailed information.)
  
  ○ **Intramural DOD Collaborator(s):** Complete a separate DOD military budget, using Suggested Collaborating DOD Military Facility Budget Format (available for download on the eBRAP “Funding Opportunities & Forms” web page [https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm)), and upload to Grants.gov attachment form as Attachment 13. (Refer to the General Application Instructions, Section III.A.8, for detailed information.)

**II.D.3. Unique Entity Identifier (UEI) and System for Award Management (SAM)**

The applicant organization must be registered as an entity in SAM (https://www.sam.gov/SAM/) and receive confirmation of an “Active” status before submitting an application through Grants.gov. *As of April 2022, all federal awards including, but not limited to, contracts, grants, and cooperative agreements will use the UEI generated through SAM.gov.* Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements.

**II.D.4. Submission Dates and Times**

All submission dates and times are indicated in Section I, Overview of the Funding Opportunity. Pre-application and application submissions are required. The pre-application and application submission process should be started early to avoid missing deadlines. There are no grace periods. Failure to meet either of these deadlines will result in submission rejection.

**Applicant Verification of Full Application Submission in eBRAP**

*For Both Extramural and Intramural Applicants:* eBRAP allows an organization’s representatives and PIs to view and modify the full application submissions associated with them. Following retrieval and processing of the full application, eBRAP will notify the organizational representatives and PI by email to log into eBRAP to review, modify, and verify the full application submission. eBRAP will validate full application files against the specific program announcement requirements, and discrepancies will be noted in an email to the PI and in the “Full Application Files” tab in eBRAP. eBRAP does not confirm the accuracy of file content. Application viewing, modification, and verification in eBRAP are strongly recommended, but not required. It is the applicant’s responsibility to review all application components and ensure proper ordering as specified in the program announcement. *If either the*
Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated full application package must be submitted prior to the application submission deadline. The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline. Other application components may be changed until the end of the application verification period. Verify that subaward budget(s) and budget justification forms are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period. After the end of the application verification period, the full application cannot be modified.

Extramural Submission: The full application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the application verification period. During the application verification period, the full application package, with the exception of the Project Narrative and Budget Form, may be modified.

Intramural DOD Submission: After eBRAP has processed the full application, the organizational Resource Manager/Comptroller/Task Area Manager or equivalent Business Official and PI(s) will receive email notification of the status and will be able to view and modify application components in eBRAP. During the application verification period, the full application package, with the exception of the Project Narrative and Budget Form, may be modified. The Resource Manager/Comptroller/Task Area Manager or equivalent Business Official should log into eBRAP to review and to approve the application package prior to the application verification deadline.

For All Submissions: Verify that subaward budget(s) with budget justification are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period.

II.D.5. Funding Restrictions

Clinical Research Extension Award (single PI):

The maximum period of performance is 4 years.

The application’s direct costs budgeted for the entire period of performance should not exceed $5M. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate.

Clinical Research Extension Award with Partnering PI Option:

The maximum period of performance is 4 years.

The applications’ combined direct costs budgeted for the entire period of performance in the applications of the Initiating PI and the Partnering PI should not exceed $6M. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization’s negotiated rate.

A separate award will be made to each PI’s organization.
For Both Clinical Research Extension Award Options:

All direct and indirect costs of any subaward or contract must be included in the total direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 4 years.

For this award mechanism, direct costs may be requested for (not all-inclusive):

- Travel in support of multidisciplinary collaborations.
- Costs for three investigators to travel to one scientific/technical meeting per year. The intent of travel costs to scientific/technical meetings is to present project information or disseminate project results of the FY23 BCRP Clinical Research Extension Award.

Must not be requested for:

- Clinical trial costs

For extramural awards with an intragovernmental component, direct transfer of funds from an extramural award recipient to a DOD or other federal agency is not allowed except under very limited circumstances. Funding to intramural DOD and other federal agencies will be managed through a direct funds transfer. Intramural applicants are responsible for coordinating through their agency’s procedures the use of contractual or assistance funding awards or other appropriate agreements to support extramural collaborators.

Refer to the General Application Instructions, Section III.A.5, for budget regulations and instructions for the Research & Related Budget. For federal agencies or organizations collaborating with federal agencies, budget restrictions apply as are noted in the General Application Instructions, Section III.A.5.

II.D.6. Other Submission Requirements

Refer to the General Application Instructions, Appendix 4, for detailed formatting guidelines.

II.E. Application Review Information

II.E.1. Criteria

II.E.1.a. Peer Review

To determine technical merit, all applications will be evaluated according to the following scored criteria, which are of equal importance:
• **Impact**

*Note:* Reviewers will evaluate how the proposed research will have an impact on the overarching challenge(s), assuming the objective/goals are realized.

- To what degree the proposed extension of a clinical research study (or studies) will have a major impact on at least one of the overarching challenges.
- To what degree the project will accelerate the progress toward ending breast cancer.
- To what degree the project will increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to limited or early termination of follow-up and sample collection and analysis.
- How well the application justifies how the identified breast cancer patients or at-risk individuals would benefit from the proposed research.

• **Research Strategy and Feasibility**

- How well the scientific rationale supports the proposed research and its feasibility, as demonstrated by logical reasoning, a critical review and analysis of the published literature, and the presentation of preliminary data.
- Whether the application adequately describes how proposed work aims to extend the data collection, follow-up, and/or analysis of a breast cancer clinical research study (or studies).
- Whether the clinical relevance of the proposed research is appropriately described.
- How well the hypothesis, objectives, and specific aims are developed.
- How well the experimental design, methods, and analyses are developed and support completion of the specific aims.
- How well the application acknowledges potential problems and addresses alternative methods and approaches.
- How well the SOW indicates a feasible plan and timeline to conduct the research and provides clearly defined milestones to be accomplished by the end of each year in the period of performance.
- Whether the application provides sufficient evidence to support the availability of and access to the resources, patient populations, and/or samples required for the study and whether the plan for the recruitment of subjects or the acquisition of samples is sufficient for the proposed research project (if applicable).
- Whether the strategy for the inclusion of women and minorities and distribution of proposed enrollment are appropriate for the proposed research (if applicable).
○ If applicable, whether data will be appropriately reported and documented to support a regulatory filing with the FDA.

○ For applications including correlative studies, to what extent the pre-existing cohort is appropriate for the objective of the study and whether the application provides sufficient evidence to demonstrate access to the pre-existing cohort biospecimens and/or data.

**Statistical Plan**

○ To what extent the statistical model and data analysis plan support the stated hypothesis or objective.

○ How well the sample size projections and appropriate power analysis, if applicable, demonstrate that the sample size is appropriate to meet the objectives of the study.

**Personnel**

○ Whether the application includes an appropriate and robust research team with the combined backgrounds and breast cancer-related expertise to enable successful conduct of the project.

○ Whether two or more consumer advocates are named in the application and meet the criteria according to the program announcement.

○ How well the consumer advocates knowledge of current breast cancer issues and how their background and/or training in breast cancer research will contribute to the proposed research.

○ How well the consumer advocates are integrated into the design and execution of the study.

○ How appropriate the levels of effort are for successful conduct of the proposed work.

**Partnership** (*only applicable to Partnering PI Option applications*)

○ How well the partnership and combined expertise of the Initiating and Partnering PIs contribute to the research strategy and completion of the SOW.

○ To what degree the partnership will better address the research question together rather than through separate individual efforts.

○ How well the application reflects that both PIs contribute equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project.

○ Whether funding will be balanced between both PIs or is otherwise appropriately justified.
• **Transition Plan**
  
  ○ How well the application demonstrates feasible methods and strategies to move the project’s findings to the next phase of development, clinical trials, clinical implementation, and/or delivery to the commercial market after successful completion of the award.
  
  ○ Whether the application appropriately addresses available opportunities (e.g., collaborations and other resources) and potential barriers that could impact the progress of commercializing and/or translating the study results into clinical practice.
  
  ○ Whether the timeline for expected post-award progress is reasonable and contains appropriate milestones and deliverables for advancing the study results toward clinical impact.
  
  ○ To what degree plans to distribute the findings to the breast cancer community are appropriate.
  
  ○ Whether the application has an appropriate plan to share the experimental platforms and molecular data generated from the proposed research with the scientific community (if applicable).

In addition, the following **unscored criteria** will also contribute to the overall evaluation of the application:

• **Environment**
  
  ○ To what degree the scientific environment is appropriate for the proposed research.
  
  ○ How well the research requirements are supported by the availability of and access to facilities and resources (including collaborative arrangements).
  
  ○ To what degree the quality and extent of institutional support are appropriate for the proposed research.
  
  ○ If applicable, to what degree the intellectual and material property plan is appropriate.

• **Budget**
  
  ○ Whether the **direct** costs exceed the allowable direct costs as published in the program announcement.
  
  ○ Whether the budget is appropriate for the proposed research.

• **Application Presentation**
  
  ○ To what extent the writing, clarity, and presentation of the application components influence the review.
II.E.1.b. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of the peer reviewers
- Relevance to the mission of the Defense Health Program and FY23 BCRP, as evidenced by the following:
  - Adherence to the intent of the award mechanism
  - Program portfolio composition
  - Programmatic relevance to the FY23 BCRP Overarching Challenges
  - Relative clinical impact

II.E.2. Application Review and Selection Process

All applications are evaluated by scientists, clinicians, and consumers in a two-tier review process. The first tier is peer review, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is programmatic review, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are made to the Commanding General, USAMRDC. The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in Section II.E.1.b, Programmatic Review. Additional information about the two-tier process used by the CDMRP can be found at https://cdmrp.health.mil/about/2tierRevProcess. An information paper describing the funding recommendations and review process for the award mechanisms for the BCRP will be provided to the PI(s) and posted on the CDMRP website.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a statement declaring that application and evaluation information will not be disclosed outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review and approval process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panel members or applicants that compromise the confidentiality of the review and approval process may also result in suspension or debarment from federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with 18 USC 1905.
II.E.3. Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in 2 CFR 200.1, over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the Federal Awardee Performance and Integrity Information System (FAPIIS).

An applicant organization may review FAPIIS, accessible through SAM, and submit comments to FAPIIS on any information about the organization that a federal awarding agency previously entered and is currently available in FAPIIS.

The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant’s integrity, business ethics, and record of performance under federal awards when determining a recipient’s qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

II.E.4. Anticipated Announcement and Federal Award Dates

All application review dates and times are indicated in Section I, Overview of the Funding Opportunity.

Each PI and organization will receive email notification of posting of the funding recommendation in eBRAP. Each PI will receive a peer review summary statement on the strengths and weaknesses of the application.

II.F. Federal Award Administration Information

II.F.1. Federal Award Notices

Awards supported with FY23 funds are anticipated to be made no later than September 30, 2024. Refer to the General Application Instructions, Appendix 2, for additional award administration information.

After email notification of application review results through eBRAP, and if selected for funding, a representative from the USAMRAA will contact the Business Official authorized to negotiate on behalf of the PI’s organization.

Pre-Award Costs: An institution of higher education, hospital, or non-profit organization may, at its own risk and without the government’s prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award. Refer to the General Application Instructions, Section III.A.5.

Only an appointed USAMRAA Grants Officer may obligate the government to the expenditure of funds. No commitment on the part of the government should be inferred from discussions
with any other individual. **The award document signed by the Grants Officer is the official authorizing document.**

**Federal Government Organizations:** Funding made to federal government organizations (to include intramural DOD organizations) will be executed through the Military Interdepartmental Purchase Request (MIPR) or Funding Authorization Document (FAD) process. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intramural applicants and collaborators are reminded to coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

**II.F.1.a. PI Changes and Award Transfers**

Changes in PI, Initiating PI, or Partnering PI are not allowed, except under extenuating circumstances that will be evaluated on a case-by-case basis and at the discretion of the Grants Officer.

An organizational transfer of an award supporting the Initiating PI or Partnering PI is discouraged and will be evaluated on a case-by-case basis and only allowed at the discretion of the Grants Officer.

An organizational transfer of an award will not be allowed in the last year of the (original) period of performance or any extension thereof.

Refer to the General Application Instructions, Appendix 2, Section B, for general information on organization or PI changes.

**II.F.2. Administrative and National Policy Requirements**

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

Refer to the General Application Instructions, Appendix 2, for general information regarding administrative requirements.

Refer to the General Application Instructions, Appendix 5, for general information regarding national policy requirements.

Refer to full text of the latest DoD R&D General Terms and Conditions and the USAMRAA General Research Terms and Conditions: Addendum to the DoD R&D General Terms and Conditions for further information.

Certification Regarding Disclosure of Funding Sources. The proposing entity must comply with Section 223(a) of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021, which requires that the PI, Partnering PIs (if applicable), and all key personnel:
• Certify that the current and pending support provided on the application is current, accurate, and complete;

• Agree to update such disclosure at the request of the agency prior to the award of support and at any subsequent time the agency determines appropriate during the term of the award; and

• Have been made aware of the requirements under Section 223(a)(1) of this Act.

False, fictitious, or fraudulent statements or claims may result in criminal, civil, or administrative penalties (18 USC 1001).

II.F.3. Reporting

Refer to the General Application Instructions, Appendix 2, Section A, for general information on reporting requirements. If there are technical reporting requirement delinquencies for any existing USAMRAA-sponsored awards at the applicant organization, no new awards will be issued to the applicant organization until all delinquent reports have been submitted.

Annual progress reports as well as a final progress report will be required.

The Award Terms and Conditions will specify if additional and/or more frequent reporting is required.

Award Expiration Transition Plan: An Award Expiration Transition Plan must be submitted with the final progress report. Use the one-page template “Award Expiration Transition Plan,” available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) under the “Progress Report Formats” section. The Award Expiration Transition Plan must outline whether and how the research supported by this award will progress and must include source(s) of funding, either known or pending.

PHS Inclusion Enrollment Reporting Requirement (only required for clinical research studies): Enrollment reporting on the basis of sex/gender, race, and/or ethnicity will be required with each annual and final progress report. The PHS Inclusion Enrollment Report is available on the “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) in eBRAP.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant, and cooperative agreement awards with a cumulative total value greater than $10M are required to provide information to FAPIIS about certain civil, criminal, and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil, and administrative proceedings as specified in the applicable Representations (see General Application Instructions, Appendix 5, Section B).
II.G. Federal Awarding Agency Contacts

II.G.1. eBRAP Help Desk

Questions related to program announcement content or submission requirements as well as questions related to the pre-application or intramural application submission through eBRAP should be directed to the eBRAP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET (closed on most U.S. federal holidays). Response times may vary depending upon the volume of inquiries.

   Phone: 301-682-5507
   Email: help@eBRAP.org

II.G.2. Grants.gov Contact Center

Questions related to extramural application submission through Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. federal holidays). Note that the eBRAP Help Desk is unable to provide technical assistance with Grants.gov submission.

   Phone: 800-518-4726; International 1-606-545-5035
   Email: support@grants.gov

Sign up on Grants.gov for “send me change notification emails” by following the link on the “Synopsis” page for the program announcement or by responding to the prompt provided by Grants.gov when first downloading the Grants.gov application package. If the Grants.gov application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.

II.H. Other Information

II.H.1. Program Announcement and General Application Instructions Versions

Questions related to this program announcement should refer to the program name, the program announcement name, and the program announcement version code 800c. The program announcement numeric version code will match the General Application Instructions version code 800.

II.H.2. Administrative Actions

After receipt of applications, the following administrative actions may occur:
II.H.2.a. Rejection

The following will result in administrative rejection of the application:

- Pre-application was not submitted.
- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.

II.H.2.b. Modification

- Pages exceeding the specific limits will be removed prior to review for all documents other than the Project Narrative.
- Documents not requested will be removed.

II.H.2.c. Withdrawal

The following may result in administrative withdrawal of the application:

- An FY23 BCRP Programmatic Panel member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation. A list of the FY23 BCRP Programmatic Panel members can be found at https://cdmrp.health.mil/bcrp/panels/panels23.

- The application fails to conform to this program announcement description.

- Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.

- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).

- To preserve the integrity of its peer and programmatic review processes, the CDMRP discourages inclusion of any employee of its review contractors having any role in the preparation, research or other duties for submitted applications. For FY23, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website (https://cdmrp.health.mil/about/2tierRevProcess). Applications that include names of personnel from either of these companies may be administratively withdrawn.

- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.

- Applications from extramural organizations, including non-DOD federal agencies, received through eBRAP may be withdrawn.
• Applications submitted by an intramural DOD organization may be withdrawn if the intramural organization cannot coordinate the use of contractual, assistance, or other appropriate agreements to provide funds to extramural collaborators.

• Submission of the same research project to different funding opportunities within the same program and funding cycle.

• The application does not address at least one of the FY23 BCRP Overarching Challenges in Section II.A.2 and adequate justification for exception was not provided.

• Application fails to include two consumer advocates on the research team as required by this program announcement.

• A clinical trial is proposed.

• **Partnering PI Option:** Failure to submit both associated (Initiating PI and Partnering PI) applications by the application submission deadline.

**II.H.2.d. Withhold**

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.
### II.H.3. Application Submission Checklist

<table>
<thead>
<tr>
<th>Application Components</th>
<th>Action</th>
<th>Initiating PI Completed</th>
<th>Partnering PI Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF424 Research &amp; Related Application for Federal Assistance (extramural submissions only)</td>
<td>Complete form as instructed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Summary (Tab 1) and Application Contacts (Tab 2) (intramural submissions only)</td>
<td>Complete tabs as instructed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Attachments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Narrative: Upload as Attachment 1 with file name “ProjectNarrative.pdf”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supporting Documentation: Upload as Attachment 2 with file name “Support.pdf”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Technical Abstract: Upload as Attachment 3 with file name “TechAbs.pdf”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lay Abstract: Upload as Attachment 4 with file name “LayAbs.pdf”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statement of Work: Upload as Attachment 5 with file name “SOW.pdf”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Impact Statement: Upload as Attachment 6 with the file name “Impact.pdf”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partnership Statement: Upload as Attachment 7 with the file name “Partnership.pdf” if applicable</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research Team Statement: Upload as Attachment 8 with the file name “Team.pdf”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transition Plan: Upload as Attachment 9 with the file name “Transition.pdf”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion of Women and Minorities: Upload as Attachment 10 with the file name “Inclusion.pdf” if applicable</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Submissions Statement: Upload as Attachment 11 with the file name “Submissions.pdf” if applicable</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Representations (extramural submissions only): Upload as Attachment 12 with file name “RequiredReps.pdf”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Application Components</td>
<td>Action</td>
<td>Initiating PI Completed</td>
<td>Partnering PI Completed</td>
</tr>
<tr>
<td>------------------------------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>-------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td></td>
<td>Suggested Collaborating DOD Military Facility Budget Format: Upload as Attachment 13 with file name “MFBudget.pdf” if applicable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Personal Data</td>
<td>Complete form as instructed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Senior/Key Person Profile (Expanded)</td>
<td>Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person to the appropriate field</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Budget (extramural submissions only)</td>
<td>Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Budget (intramural submissions only)</td>
<td>Complete the Suggested DOD Military Budget Format, including justification</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project/Performance Site Location(s) Form</td>
<td>Complete form as instructed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Subaward Budget Attachment(s) Form</td>
<td>Complete form as instructed</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### APPENDIX 1: ACRONYM LIST

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCRP</td>
<td>Breast Cancer Research Program</td>
</tr>
<tr>
<td>CDMRP</td>
<td>Congressionally Directed Medical Research Programs</td>
</tr>
<tr>
<td>CFR</td>
<td>Code of Federal Regulations</td>
</tr>
<tr>
<td>DOD</td>
<td>Department of Defense</td>
</tr>
<tr>
<td>DoDGARs</td>
<td>Department of Defense Grant and Agreement Regulations</td>
</tr>
<tr>
<td>eBRAP</td>
<td>Electronic Biomedical Research Application Portal</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics Committee</td>
</tr>
<tr>
<td>ET</td>
<td>Eastern Time</td>
</tr>
<tr>
<td>FAPIIS</td>
<td>Federal Awardee Performance and Integrity Information System</td>
</tr>
<tr>
<td>FDA</td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>FY</td>
<td>Fiscal Year</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>LOI</td>
<td>Letter of Intent</td>
</tr>
<tr>
<td>M</td>
<td>Million</td>
</tr>
<tr>
<td>MB</td>
<td>Megabytes</td>
</tr>
<tr>
<td>NIH</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>OHARO</td>
<td>Office of Human and Animal Research Oversight (previously Office of Research Protections)</td>
</tr>
<tr>
<td>OHRO</td>
<td>Office of Human Research Oversight (previously Human Research Protection Office)</td>
</tr>
<tr>
<td>ORCID</td>
<td>Open Researcher and Contributor ID, Inc.</td>
</tr>
<tr>
<td>PDF</td>
<td>Portable Document Format</td>
</tr>
<tr>
<td>PHS</td>
<td>Public Health Service</td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>SAM</td>
<td>System for Award Management</td>
</tr>
<tr>
<td>SOW</td>
<td>Statement of Work</td>
</tr>
<tr>
<td>STEM</td>
<td>Science, Technology, Engineering, and/or Mathematics</td>
</tr>
<tr>
<td>UEI</td>
<td>Unique Entity Identifier</td>
</tr>
<tr>
<td>URL</td>
<td>Uniform Resource Locator</td>
</tr>
<tr>
<td>USAMRAA</td>
<td>U.S. Army Medical Research Acquisition Activity</td>
</tr>
<tr>
<td>USAMRDC</td>
<td>U.S. Army Medical Research and Development Command</td>
</tr>
<tr>
<td>USC</td>
<td>United States Code</td>
</tr>
</tbody>
</table>